Overview Pioglitazone on Pancreatic Steatosis and Bone Health Status: Completed Trial end date: 2013-12-01 Target enrollment: Participant gender: Summary Randomized, double blind, placebo controlled trial evaluating the effect of pioglitazone on pancreatic fat content and bone turnover markers. Phase: N/A Details Lead Sponsor: University of Texas Southwestern Medical CenterCollaborator: National Institutes of Health (NIH)Treatments: Pioglitazone